Roche makes stealth move to block Biocon, Mylan's biosim Herceptin in India

It's probably akin to a well-executed stealth bomber attack. Roche, which appeared to be silently watching the action as partners Biocon and Mylan announced plans to launch their biosimilar versions of Herceptin (trastuzumab) in India, has now moved the Delhi High Court alleging a clutch of irregularities in the biosimilars' journey to the market.